疑难病杂志2017，Vol.16Issue(8)：769-772,4.DOI:10.3969/j.issn.1671-6450.2017.08.004
新型口服抗凝剂与华法林在非瓣膜性心房颤动患者中的应用分析
The usage of novel oral anticoagulants and warfarin in patients with non valvular atrial fibrillation
摘要
Abstract
Objective To analyze the application of novel oral anticoagulants and warfarin in patients with non valvular atrial fibrillation,in order to prevent stroke and reduce the risk of bleeding.Methods Five hundred and sixteen patients with non valvular atrial fibrillation who received anticoagulation therapy were enrolled from January 2015 to December 2016.The basic clinical data and complications of patients were collected,in order to compare the application between the NOAC and warfarin.Results From 2015 to 2016,the rate of NOAC increased from 4.5％to 18.7％(x2=25.331,P=0.001),while the rate of aspirin decreased from 39.4％to 20.6％(x2=21.510,P=0.001).The rate of Warfarin and clopidogrel remained relatively stable(33.0％,36.9％,x2=0.886,P=0.347;12.9％,13.1％,x2=0.005,P=0.942).The scores of CHA2DS2VASc,HAS-BLED and age between the patients taking NOAC and warfarin were respectively(1.5±1.2 vs.2.0±1.5,t=2.877,P=0.005;1.1±0.8 vs.1.5±1.0,t=2.904,P=0.004;61.1±12.5 vs.66.0±9.9,t=2.768,P=0.007),the differences were statistically significant.Conclusion The rate of NOAC increased rapidly from 2015 to 2016,and it was mainly recommended for patients with lower CHA2DS2VASc and HAS-BLED scores and younger patients.The rate of warfarin remained stable,however,the ratio of aspirin and clopidogrel were still high.关键词
心房颤动,非瓣膜性/新型口服抗凝剂/华法林/CHA2DS2VAScKey words
Atrial fibrillation/non valvular/Novel oral anticoagulants/Warfarin/CHA2DS2VASc引用本文复制引用
梁飒,黄锐,郑雅格,黄从新..新型口服抗凝剂与华法林在非瓣膜性心房颤动患者中的应用分析[J].疑难病杂志,2017,16(8):769-772,4.基金项目
湖北省科技创新专项(重大项目)(2016ACA153) （重大项目）
